Servier and the pharmatech Aqemia have entered into a collaboration agreement to accelerate the discovery of small molecule therapeutic drug candidates in immuno-oncology.
This collaboration will use Aqemia’s technology based on artificial intelligence and quantum physics. Aqemia will take responsibility for the AI-based design to deliver optimized molecules that fulfill several small molecule design goals. Unlike most AI-based technologies that need experimental data to train their algorithms prior to starting the design, Aqemia will tackle the project from the earliest stage of the drug discovery by generating its own data with quantum and statistical physics-based calculations.
Olivier Nosjean, Head of Open Innovation and Scientific Affairs at Servier R&D: “This collaboration with Aqemia is a concrete example of Servier working side by side with a start-up to create value for both parties, working jointly to accelerate therapeutic innovation for patients. This collaboration is the result of the Start-up @ Servier program, where an initial phase of joint work allows us to carry out a key study or pilot application of a technology, before entering into a classic collaboration. This is our first application of this Start-up @ Servier model, and we are very happy to see it take shape with Aqemia, which is such a promising collaboration.”